CA3127973A1 - Inhaled administration of lipocalin muteins - Google Patents

Inhaled administration of lipocalin muteins Download PDF

Info

Publication number
CA3127973A1
CA3127973A1 CA3127973A CA3127973A CA3127973A1 CA 3127973 A1 CA3127973 A1 CA 3127973A1 CA 3127973 A CA3127973 A CA 3127973A CA 3127973 A CA3127973 A CA 3127973A CA 3127973 A1 CA3127973 A1 CA 3127973A1
Authority
CA
Canada
Prior art keywords
leu
lipocalin mutein
ser
tyr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127973A
Other languages
English (en)
French (fr)
Inventor
Gabriele Matschiner
Ahmed Mousa
Vanessa WELK
Gary Anderson
Christine Wright
Thomas Jaquin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of CA3127973A1 publication Critical patent/CA3127973A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3127973A 2019-03-29 2020-03-27 Inhaled administration of lipocalin muteins Pending CA3127973A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962826767P 2019-03-29 2019-03-29
US62/826,767 2019-03-29
EP19166435 2019-04-01
EP19166435.8 2019-04-01
EP19175818.4 2019-05-22
EP19175818 2019-05-22
EP19177568 2019-05-31
EP19177568.3 2019-05-31
EP19211404.9 2019-11-26
EP19211404 2019-11-26
PCT/EP2020/058637 WO2020201038A1 (en) 2019-03-29 2020-03-27 Inhaled administration of lipocalin muteins

Publications (1)

Publication Number Publication Date
CA3127973A1 true CA3127973A1 (en) 2020-10-08

Family

ID=70292935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127973A Pending CA3127973A1 (en) 2019-03-29 2020-03-27 Inhaled administration of lipocalin muteins

Country Status (8)

Country Link
US (1) US20220168387A1 (enExample)
EP (1) EP3946417A1 (enExample)
JP (1) JP2022526367A (enExample)
KR (1) KR20210146999A (enExample)
CN (1) CN113939307A (enExample)
AU (1) AU2020253034A1 (enExample)
CA (1) CA3127973A1 (enExample)
WO (1) WO2020201038A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
KR20230121785A (ko) * 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) * 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP2046820B1 (en) 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
CN101932598B (zh) 2008-01-30 2016-12-21 皮里斯股份公司 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
RU2707126C2 (ru) * 2009-12-07 2019-11-22 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
PL2580236T3 (pl) * 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
AU2012350654C1 (en) * 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
EP3842058B1 (en) * 2011-12-13 2023-08-23 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
MY175188A (en) * 2012-01-09 2020-06-13 Pieris Ag Methods for preventing, treating or diagnosing disorders
US9522940B2 (en) * 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US10526384B2 (en) * 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015177175A2 (en) * 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
CR20170425A (es) 2015-02-18 2017-11-22 Sanofi Sa Nuevas proteínas específicas para pioverdina y pioquelina
JP6783797B2 (ja) * 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
CN114573680A (zh) * 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白
EP3298030B1 (en) * 2015-05-18 2023-01-18 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
MX2017014730A (es) 2015-05-18 2018-06-28 Pieris Pharmaceuticals Gmbh Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
WO2017009456A1 (en) * 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CA3050194A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
FI3830120T3 (fi) * 2018-07-31 2023-06-13 Pieris Pharmaceuticals Gmbh CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
US20210246219A1 (en) * 2018-08-27 2021-08-12 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
SG11202106353VA (en) * 2019-02-26 2021-07-29 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
US20220193191A1 (en) * 2019-03-29 2022-06-23 Astrazeneca Ab Lipocalin mutein for treatment of asthma
EP4161957A1 (en) * 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Multimeric immunomodulator targeting 4-1bb
JP2023541482A (ja) * 2020-09-18 2023-10-02 ピエリス ファーマシューティカルズ ゲーエムベーハー バイオマーカー法および使用法

Also Published As

Publication number Publication date
JP2022526367A (ja) 2022-05-24
KR20210146999A (ko) 2021-12-06
CN113939307A (zh) 2022-01-14
AU2020253034A1 (en) 2021-08-19
EP3946417A1 (en) 2022-02-09
WO2020201038A1 (en) 2020-10-08
US20220168387A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7441589B2 (ja) Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
EP3685854A1 (en) Methods of treating a tauopathy
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
US20220168387A1 (en) Inhaled administration of lipocalin muteins
JP6793748B2 (ja) 放射性および化学的損傷を予防及び治療するための方法
US12173061B2 (en) Compositions and methods for treatment of chronic lung diseases
WO2020072805A1 (en) Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
US20240228562A1 (en) Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
HK40051700A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40031459A (en) Methods of treating a tauopathy
HK40043983A (en) Methods of treating a tauopathy
JP2021518417A (ja) 肺の修復に関する方法および組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803